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Abstract
Pyocyanin is a small molecule produced by Pseudomonas aeruginosa that plays a crucial role in the pathogenesis of infections by
this notorious opportunistic pathogen. The inhibition of pyocyanin production has been identified as an attractive antivirulence
strategy for the treatment of P. aeruginosa infections. Herein, we report the discovery of an inhibitor of pyocyanin production in
cultures of wild-type P. aeruginosa which is based around a 4-alkylquinolin-2(1H)-one scaffold. To the best of our knowledge, this
is the first reported example of pyocyanin inhibition by a compound based around this molecular framework. The compound may
therefore be representative of a new structural sub-class of pyocyanin inhibitors, which could potentially be exploited in in a thera-
peutic context for the development of critically needed new antipseudomonal agents. In this context, the use of wild-type cells in
this study is notable, since the data obtained are of direct relevance to native situations. The compound could also be of value in
better elucidating the role of pyocyanin in P. aeruginosa infections. Evidence suggests that the active compound reduces the level
of pyocyanin production by inhibiting the cell–cell signalling mechanism known as quorum sensing. This could have interesting
implications; quorum sensing regulates a range of additional elements associated with the pathogenicity of P. aeruginosa and there
is a wide range of other potential applications where the inhibition of quorum sensing is desirable.
Findings
The Gram-negative bacterium Pseudomonas aeruginosa is a
clinically important opportunistic human pathogen [1]. This
opportunistic pathogen is well known to be a challenging infec-
tion to completely eradicate in infected patients due to high
levels of intrinsic resistance to a wide variety of antibiotics
[1-6] and the tendency of P. aeruginosa cells to form antibiotic-
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resistant biofilms [7-9]. The incidence of multidrug-resistant
P. aeruginosa infections is on the rise on a global scale [8-10]
and this bacterium is now considered to have joined the ranks of
the ‘superbugs’ [1]. Thus, there is an urgent need to discover
new therapeutic strategies to combat P. aeruginosa infections
[1-12].
P. aeruginosa can secrete small organic molecules, exoen-
zymes, tissue degrading enzymes, toxins and other substrates
which damage physiological functions of the host causing
disease, often termed ‘virulence factors’ [13-16]. Pyocyanin is
an important redox active small molecule virulence factor
which is widely considered to play a crucial role in the patho-
genesis of P. aeruginosa infections (Figure 1) [8,9,17,18]. The
inhibition of pyocyanin production has been identified as an
attractive antivirulence strategy for the treatment of P. aerugi-
nosa infections [8,9,19]. Herein, we report the discovery of a
potent inhibitor of pyocyanin production in cultures of wild-
type P. aeruginosa which is based around a 4-alkylquinolin-
2(1H)-one framework. To the best of our knowledge, this is the
first reported example of the inhibition of this phenotype by a
member of this structural sub-class. Thus, a promising new
scaffold for pyocyanin inhibition has been identified.
Figure 1: BHL and OdDHL are two natural AHL-based signaling mole-
cules used by P. aeruginosain quorum sensing. PQS is a natural
quinolone signaling molecule also used by P. aeruginosa in quorum
sensing. Pyocyanin is a P. aeruginosa virulence factor. Compound 1 is
an abiotic OdDHL-mimic which can inhibit pyocyanin production [8,9].
A cell–cell signalling process known as quorum sensing regu-
lates pyocyanin production by P. aeruginosa [8,9,20]. This
bacterium uses (at least) three different types of quorum sensing
systems. Two of the QS signaling systems in P. aeruginosa
utilise N-acylated-L-homoserine lactones (AHLs) as signalling
molecules [20-22]. The rhl system utilises N-butanoyl-L-
homoserine lactone (BHL) and it’s cognate receptor RhlR [20-
22]. The las system utilises N-(3-oxododecanoyl)-L-homoserine
lactone (OdDHL) and it’s cognate receptor LasR (Figure 1) [20-
22]. Interlinking these two AHL signalling systems is a third
signaling system utilising a quinolone signalling molecule
(termed Pseudomonas quinolone signal, PQS) [20] to form an
intricate hierarchical signaling network with the Las system at
the top of the network. The regulator of the pyocyanin biosyn-
thesis genes is RhlR and transcription of the rhlR gene is itself
regulated by LasR. Hence, it has been hypothesised that LasR
inhibition should result in the attenuation of pyocyanin produc-
tion [8,9,20]. This hypothesis has been validated with a number
of synthetic small molecules which inhibit LasR and pyocyanin
production, respectively [8,9,20,23-26]. Many such inhibitors of
pyocyanin biosynthesis are based on the same general struc-
tural framework as OdDHL. For example, we have recently re-
ported the discovery of various OdDHL mimics which can
inhibit pyocyanin production in cultures of wild-type P. aerugi-
nosa, with compound 1 found to be the most potent (Figure 1)
[9]. Inspired by these results, we sought to examine the ability
of other OdDHL analogues to inhibit this phenotype. Our stan-
dard synthetic route towards these derivatives involves cou-
pling of 2 with aromatic amines to generate the corresponding
amides, followed by acetal group removal under acidic condi-
tions (Scheme 1) [9]. However, when the product of the reac-
tion of 2 with 3 was treated with TFA, compound 4 was gener-
ated (Scheme 1). The protected amide intermediate is known to
form; presumably upon treatment with acid the liberated ketone
group is then attacked intramolecularly by the electron-rich aro-
matic ring system to form the bicyclic ring system. Other syn-
thetic routes to such 4-alkylquinolin-2(1H)-one analogues
involve intramolecular cyclisation of an analogous β-ketoamide
in sulphuric acid [27], or pallidum catalysed intramolecular
cyclisation of an acetylene derivative under acidic conditions
[28].
Scheme 1: Unexpected synthesis of compound 4. The synthesis of 2
was achieved by a previously reported route [9].
The 4-alkylquinolin-2(1H)-one molecular scaffold of com-
pound 4 is clearly distinct from that of AHLs; to the best of our
knowledge, compounds of this structural sub-class have never
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Figure 2: a) Inhibitory effect of compound 4 (200 μM suspension in DMSO) on pyocyanin production in PAO1. DMSO was added as a control. No
effect on growth was observed for the compound. b) Effect of various concentrations of 4 on pyocyanin production in PAO1. A logarithmic trend line
has been fitted to the averaged data points (calculated using Microsoft® Excel® 2011). Growth conditions in both cases: cultures of PAO1 were grown
in Luria broth medium in the presence of compound 4 (at the indicated concentration) with good aeration at 37 °C for 13 hours (initial OD600 of 0.05
t = 0). After growth, pyocyanin production was quantified as previously described [29]. The data represents the averages and standard deviations
from the results of three independent biological repeats.
been screened for the ability to modulate pyocyanin production
(or any other quorum sensing-regulated phenotypes). Thus,
quinolone 4 was evaluated for its ability to inhibit pyocyanin
production by the wild-type P. aeruginosa strain PAO1
(Figure 2a). We chose to work with wild-type cells as the data
obtained would be of more direct relevance to native situations
than if biosensor strains were used [9]. The compound was
found to be very active by this assay, inhibiting the production
of pyocyanin by 86 ± 1% without affecting bacterial growth (at
a concentration of 200 µM, tested as a suspension in DMSO).
Pleasingly this level of activity is comparable to the OdDHL-
mimic 1 (93 ± 2% inhibition of pyocyanin production deter-
mined under identical assay conditions to those described in
Figure 2) [9]. Though there are many examples of AHL-based
compounds with the ability to reduce pyocyanin production,
there are several well-documented problems associated with the
potential use of molecules based on the AHL framework in a
therapeutic context [9,12,20]. Thus, there is interest in the iden-
tification of new structural classes of small-molecule inhibitors
of pyocyanin production, such as that represented by com-
pound 4 [12]. The effect of varying the concentration of 4 upon
pyocyanin production was next examined (Figure 2b). Com-
pound 4 was found to inhibit this phenotype in a concentration-
dependent manner above 20 μM, with an IC50 ~70 μM. Interest-
ingly, this data suggests that 4 may have slight agonist activity
at low concentrations. This type of behaviour has previously
been observed for AHL-based modulators of quorum sensing.
Many such compounds have been identified that can both
slightly activate and inhibit a quorum sensing circuit depending
on their concentration [20]. This result could also potentially be
attributed to the use of wild-type cells. Endogenous AHL levels
in such systems could conceivably fluctuate in an unpredictable
fashion, which would be expected to affect the level of
pyocyanin production.
Compounds that attenuate pyocyanin biosynthesis in P. aerugi-
nosa may be inhibitors of LasR-based quorum sensing. Howev-
er, it has previously been reported that P. aeruginosa can exhib-
it near full virulence, including pyocyanin production, in the
absence of LasR utilising solely the rhl, and pqs signalling
systems [30]. Additional studies have demonstrated that the
straight forward hierarchical QS network (with the las system at
the forefront followed by the lower ranked rhl and pqs
signalling system) is more elaborate and complex than this hier-
archical structure [8,9,30]. Taking these studies into account it
is possible that pyocyanin inhibitors in P.aeruginosa are not
directly inhibiting LasR but have an alternate mode of action(s),
this hypothesis should not be completely ruled out. This may be
especially relevant for compounds such as 4, which are clearly
structurally distinct from OdDHL, the natural LasR agonist
[12].
In order to further explore the possibility that compound 4 may
act as a LasR antagonist, it was subjected to molecular docking
studies against the P. aeruginosa LasR ligand–binding domain
(LBD) [31]. Specifically, both OdDHL and 4 were docked into
the OdDHL binding pocket of two LasR LBD structures, one
with a bridging water molecule, which is known to be involved
in a hydrogen bonding between OdDHL and Arg61 (Figure 3a)
[32], and one without. In addition, both rigid and flexible con-
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formations of LasR LBD were used in the docking runs. Tyr47
and Arg61 exhibit considerable variation in their side-chain
conformations in various crystal structures of LasR LBD com-
plexes and hence, they were made flexible in the flexible recep-
tor docking runs. The best score for OdDHL (−9.1 kcal/mol)
was obtained from the rigid receptor docking run with water.
The docked and crystallographic conformations of OdDHL
agree closely with each other (root mean square deviation
[RMSD] = 0.54 Å) in the presence of the crystallographic water
molecule. The RMSD between the docked and crystallographic
conformations of OdDHL increases to 1.1 Å in the absence of
water. This demonstrates the importance of the bridging water
molecule in the accurate reproduction of the crystallographic
binding mode of OdDHL. Conversely, the best score for 4
(−9.7 kcal/mol) was obtained when it was docked into the flex-
ible conformation of LasR LBD without water. In order to
accommodate the bicyclic moiety of 4, Arg61, which points
into the OdDHL binding pocket in the crystal structure of LasR
LBD bound to OdDHL (Figure 3a) [31], is displaced out
towards the bulk solvent (Figure 3b). This alternative conforma-
tion of Arg61 has also been observed in several structures of
LasR LBD in complex with triphenyl ligands [33]. In this
docked pose, interactions between 4 and Las LBD are predomi-
nantly hydrophobic in nature as only one hydrogen bond is
formed between the oxygen of a methoxy group of 4 to Ser129.
This is in contrast to OdDHL, which forms five hydrogen bonds
as well as extensive hydrophobic interactions with LasR LBD.
Given its highly favourable docking score, it is plausible that
compound 4 may bind LasR at the OdDHL binding site, and
thus be capable of competitively disrupting OdDHL-dependent
activation of LasR and thereby inhibiting pyocyanin production.
Conclusion
In conclusion, we have reported the discovery of 4, a potent in-
hibitor of pyocyanin in wild-type P. aeruginosa. To the best of
our knowledge this is the first reported example of pyocyanin
inhibition by a compound based around a 4-alkylquinolin-
2(1H)-one scaffold. Compound 4 is therefore representative of a
new structural sub-class of pyocyanin inhibitors, which could
potentially be exploited in a therapeutic context for the develop-
ment of novel antipseudomonal agents. In this context, the use
of wild-type cells in this study is notable, since the data ob-
tained are of more direct relevance to native situations than if
biosensor strains (tailored bacterial reporter strains) were used
(which is typically the case) [9]. Conceivably 4 could also be of
value in better elucidating the role of pyocyanin in P. aerugi-
nosa infections. Of wider significance, the identification of
small molecules with antivirulence activity is needed in order to
more fully evaluate the therapeutic potential of targeting viru-
lence factors [8,9,34]. There is some evidence suggesting that 4
reduces the level of pyocyanin production by disrupting
Figure 3: Binding poses of OdDHL and compound 4 in OdDHL binding
site. Hydrogen bonds are shown in black dotted lines. a) Crystal struc-
ture of OdDHL bound to LasR LBD (PDB 2UV0 [31]). b) Top-scoring
pose of compound 4 obtained by docking into LasR LBD.
OdDHL-dependent activation of LasR; that it, compound 4,
may be a LasR antagonist and an inhibitor of LasR-based
quorum sensing. This could have interesting implications;
quorum sensing regulates a range of additional elements associ-
ated with the pathogenicity of P. aeruginosa and there is a wide
range of other potential applications where the inhibition of
quorum sensing is desirable [8,9,20]. In this context, it is worth
noting that compound 4 is structurally reminiscent of 2-alkyl-
4(1H)-quinolones, which are known to have effects upon
quorum sensing in P. aeruginosa, including pyocyanin produc-
tion [8,9,35]. Thus, the cognate receptor of PQS, PqsR, could be
a target of 4; however, other targets of 4 cannot as yet be ruled
out. Further investigations into the mode of action of 4 and
structure–activity relationship studies are ongoing and results
will be reported in due course.
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